The patent is entitled "Devices for Continuous Measurement of Glucose in Body Fluid."
D Medical Industries Ltd. (Nasdaq: DMED); TASE:DMED) has obtained a US patent for a component of its insulin pump. The patent, entitled "Devices for Continuous Measurement of Glucose in Body Fluid," protects innovative technology that allows for the combination of a minimally invasive continuous glucose monitor and an insulin pump on the same patch.
The technology enables the use of a single access point to both accurately test for blood glucose levels and deliver insulin.
D Medical COO Hezkiah Tsoory said, “The ability to accurately monitor glucose levels and deliver insulin via a single device employing a common insertion point represents a major breakthrough in the delivery of a safe, convenient and minimally invasive experience for insulin pump users."
D Medical's share price closed at $1.71 on Nasdaq yesterday, giving a market cap of $13 million, and rose 7% by mid-afternoon on the TASE today to NIS 7.03.
Published by Globes [online], Israel business news - www.globes-online.com - on November 28, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011